Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 23, 2007

Novartis Licenses MedImmune’s Reverse Genetics Technology for Flu Vaccines

  • MedImmune licensed its reverse genetics intellectual property to Novartis. The transaction will support the development and construction of new vaccine strains to produce inactivated human seasonal, prepandemic, and pandemic influenza vaccines.

    MedImmune will receive an upfront payment and has the potential to receive royalties on certain vaccine stockpiles or sales of other influenza products.

    Reverse genetics is a method by which viruses such as influenza can be generated from segments of DNA. For prospective pandemic influenza vaccines, it can be a useful technology because the process does not require manufacturers to work directly with potentially infectious pandemic strains such as H5N1 rather only segments of the virus’ genome, according to MedImmune.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »